α2-Adrenoceptors and depression

Journal of Psychopharmacology

Volumn 10, Issue SUPPL. 3, 1996, Pages 35-42

  Nutt, D J ^a   Pinder, R M ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NV ORGANON   (Netherlands)

Author keywords

2 adrenoceptors; Antidepressants; Depression; Idazoxan; Mianserin; Mirtazapine

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CATECHOLAMINE; CLONIDINE; FLUPAROXAN; IDAZOXAN; MIANSERIN; MIRTAZAPINE; NEUROTRANSMITTER; NORADRENALIN; PHENTOLAMINE; PIPEROXAN; PRESYNAPTIC RECEPTOR; RAUWOLSCINE; SEROTONIN; SEROTONIN 1 ANTAGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; TECIPTILINE; TRAZODONE; YOHIMBINE;

CATECHOLAMINE RELEASE; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; NERVE CELL STIMULATION; NORADRENALIN RELEASE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RECEPTOR BLOCKING; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

EID: 0030457961     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. 2-receptors and of amine uptake in the rat brain by the antidepressant, mianserin. Naunyn-Schmiederberg's Arch Pharmacol 300: 31-37
2. Bremner J D (1995) A double-blind comparison of Org 3770, amitriptyline and placebo in major depression. J Clin Psychiatr 56: 519-525
3. Broekkamp C L E, Leysen D, Peeters B W M, Pinder R M (1995) Prospects for improved antidepressants. J Med Chem 38: 4615-4633
4. Bylund D B, Eikenberg D C, Hieble J P, Langer S Z, Lefkowicz R J, Minneman K P, Molinoff P B, Ruffolo R R, Trendelenburg U (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46: 121-136
5. 2-adrenergic autoreceptor function in humans: Effects of oral yohimbine. Life Sci 30: 2033-2041
6. Charney D S, Heninger G R, Sternberg D E (1984) The effect of mianserin on alpha-2-adrenergic receptor function in depressed patients. Br J Psychiatr 144: 407-416
7. Charney D S, Price L H, Heninger G R (1986) Desipramineyohimbine combination treatment in refractory depression. Arch Gen Psychiatr 43: 1155-1161
8. Claghorn J L, Lesem M D (1995) A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affective Disord 34: 165-171
9. Corn T H (1994) New antidepressants-A look to the future. In Montgomery SA, Corn TH (eds), Psychopharmacology of depression. Oxford University Press, Oxford, pp. 240-252
10. Coupland N, Glue P, Nutt D J (1992) Challenge tests: Assessment of the noradrenergic and GABA systems in depression and anxiety disorders. Molec Aspects Med 13: 221-247
11. Crossley D I (1984) The effects of idazoxan, an alpha-2-adrenoceptor antagonist in depression-A preliminary investigation. 9th International Congress of Pharmacology, Abstract 1724P
12. De Boer Th, Ruigt G S F, Berendsen H M G (1995) The selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 10 (Suppl. 2): S107-S118
13. De Boer Th, Maura G, Raiteri M, De Vos C J,Wieringa J, Pinder R M (1988) Neurochemical and autonomic pharmacological profiles of the 6-aza analogue of mianserin, Org 3770, and its anantiomers. Neuropharmacology 27: 399-408
14. 2-adrenoceptor antagonists mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 277: 852-860
15. 2-adrenoceptor antagonism and depression. Drug News and Persp 4: 197-203
16. 2-methyldopa in hypertensive patients. Eur J Clin Pharmacol 24: 15-19
17. Galitzky J, Rivière D, Tran M A, Montastruc J L, Berlan M (1990) Pharmacodynamic effect of chronic yohimbine treatment in healthy volunteers. Eur J Clin Pharmacol 39: 447-451
18. 2-adrenoceptor antagonist with serotonin uptake blocking activity and putative antidepressant effects: II. Pharmacology profile. Drug Dev Res 35: 264-260
19. Grossman F (1994) A double-blind collaborative study with the NIMH and Friends Hospital comparing the clinical effects of idazoxan and bupropion in bipolar depressed patients. Abstract CINP Regional Workshop on Critical Issues in the Treatment of Affective Disorders, Paris, p. 128
20. 2-adrenoceptor antagonist mirtazpine on 5-HT neurotransmission. Soc Neurosci 21: 767 (abstract)
21. 2-adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 277: 861-871
22. 2-adrenoceptor antagonist. Br J Pharmacol 102: 887-895
23. 2-adrenergic receptor sensitivity in depression: the plasma MHPG, behavioural, and cardiovascular response to yohimbine. Arch Gen Psychiatr 45: 718-726
24. Hieble J P, Bondinell W E, Ruffolo R R (1995( α- and β-Adrenoceptors: From the gene to the clinic. 1. Milecular biology and adrenoceptor classification. J Med Chem 38: 3415-3444
25. 2-adrenoceptors. J Nucl Med Biol 19: 841-849
26. Kenko M, Kanno T, Honda K, Mashiko H, Oosuga N, Watanabe A, Rumashiro H (1992) Platelet alpha-2-adrenergic receptor binding and plasma free 3-methoxy-4-hydroxyphenyglycol in depressed patients before and after treatment with mianserin. Neuropsychobiology 25: 14-19
27. Karege F, Bovier P, Widmer J, Gaillard J-M, Tissot R (1992) Platelet membrane alpha2-adrenergic receptors in depression. Psychiatr Res 43: 243-252
28. Kasper S (1995) Clinical efficacy of mirtazapine: A review of meta analyses on pooled data. Int Clin Psychopharmacol 10 (Suppl. 4): 25-35
29. Langer S Z (1974) Presynaptic regulation of catecholamine release. Biochem Pharmacol 23: 1793-1800
30. 2-autoreceptors in rabbit atria and kidney. Naunyn-Schmiedeberg's Arch Pharmacol 352: 31-42
31. Manjii H K, Rudorfer M V, Potter W Z (1994) Affective disorders and adrenergic function. In Cameron O G (ed.), Adrenergic dysfunction and psychobiology. American Psychiatric Press, Washington DC, pp. 365-101
32. 2-Adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatr 31: 471-490.
33. Mendlewicz J, Pinder R M, Stulemeijer S M, Van Dorth R (1982) Monoamine metabolites in cerebrospinal fluid of depressed patients during treatment with mianserin or amitriptyline. J Affective Disord 4: 219-226
34. 2-adrenergic receptors. Molec Pharmacol 37: 65-68
35. 2-adrenergic heteroreceptors of 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn-Schmiedeberg's Pharmacol 347: 266-272
36. 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing NE synaptic concentration. Neuropsychopharmacology 10: 41-51
37. 2-adrenoceptor antagonist in the treatment of depression. In Dahl S G, Gram L F (eds), Clinical pharmacology in psychiatry. Springer, Berlin, pp. 105-108
38. Montgomery SA (1995) Safety of mirtazapine: A review. Int Clin Psychopharmacol 10 (Suppl. 4): 37-45
39. Montgomery S A, Bullock T, Pinder R M (1991) The clinical profile of mianserin. Nordic J Psychiatr 45 (Suppl. 24): 27-35
40. Nutt D J, Lalies M, Hudson A (1993) The effectsof alpha-2-adrenoceptor antagonists on extracellular dopamine concentration in rat striatum. In Briley M, Marien M (eds), Noradrenergic mechanisms in Parkinson's disease. Academic Press, London, pp. 159-172
41. 2-antagonist and effective sustained antidepressant in bipolar depressed patients. Arch Gen Psychiatr 46: 958-959
42. Palazidou E, Papdoupoulos A, Sitsen A, Stahl S, Checkley S (1989) An alpha-2-adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man. Psychopharmacology 37: 115-117
43. Pettibone D J, Pfleuger A B, Totaro J A (1985) Comparison of the effects of recently developed alpha-2-adrenergic antagonists with yohimbine and rauwolscine on monoamine synthesis in the rat brain. Biochem Pharmacol 34: 1093-1097
44. 2 adrenoceptors in depressive illness. Life Sci 39: 1589-1616
45. 3H-paraaminoclonidine binding to platelet purified plasma membranes from depressed patients. Neuropsychopharmacology 3: 201-210
46. Pinder R M (1991) Mianserin; pharmacological and clinical correlates. Nordic J Psychiatr 45 (Suppl. 24): 13-26
47. 2-Adrenoceptor antagonists as antidepressants: The search for selectivity. In Dahl S A, Gram L F, Paul S M, Potter W Z (eds), Clinical pharmacology in psychiatry. Springer, Berlin, pp. 107-112
48. Pinder R M, Wieringa J H (1993) Third-generation antidepressants. Med Res Rev 13: 259-325
49. 2-adrenoceptor antagonists in volunteers and depressed patients. In Montgomery S A, Corn T H (eds), Psychopharmacology of depression. Oxford University Press, Oxford, pp. 102-128
50. 2-adrenoceptors regulating central norepienphrine and serotonin release. J Pharmacol Exp Ther 224: 679-684
51. 2-adrenoceptors in human brain cortex. Br J Pharmacol 107: 1146-1151
52. 2-adrenoceptors in the human cerebral cortex. Naunyn-Schmiedeberg's Arch Pharmacol 342: 508-512
53. Ruffolo R R, Bondinell W, Hieble J P (1995) α- and β-Adrenoceptors: From the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem 38: 3681-3716
54. 2C-Adrenoceptor-modulated release of noradrenaline in human right atrium. Br J Pharmacol 116: 2617-2624
55. Schittecatte M (1995) Alpha-2 adrenergic dysfunction in depression: standardisation and validation of the clonidine REM suppression test. Eur Neuropsychopharmacol 5: 166
56. 2-receptor blockade in addition to tricyclic antidepressants in therapy-resistant depression. J Clin Psychopharmacol 8: 108-111
57. 2-adrenoceptor antagonist, MK-467, on the metabolic and cardiovascular response to exercise in healthy man. Br J Clin Pharmacol 37: 39-44
58. Sitsen J M A, Zivkov M (1995) Mirtazapine. Clinical profile. CNS Drugs 4 (Suppl. 1): 39-48
59. Smith W T, Glaudin V, Panagides J, Gilvary E (1990) Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 26: 191-196
60. Sramek JJ, Jasinsky O, Chang S, Shu V, Kashkin K, Kennedy S, Sadd C, Cutler NR (1995) Pilot efficacy trial of ABT-200 in patients with major depressive disorder. Depression 2: 315-318
61. 2-autoreceptors. Naunyn-Schmiedeberg's Arch Pharmacol 349: 25-33
62. Zivkov M, Roes K C B, Pols A G (1995) Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: A meta analysis. Hum Psychopharmacol 10 (Suppl. 2): S135-S145